Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Boston Biotech, Anodyne Nanotech Advances the Hero Patch Platform by Securing $4.2M in Seed Financing

Anodyne Nanotech, Inc.

Anodyne Nanotech, Inc., a Boston-based biotechnology company developing differentiated, transdermal forms of high-value drugs, announced today that it has raised $4,200,000 to expand its Hero Patch™ platform. Lead investors were Velocity Partners, Relativity Healthcare Fund, and Big Pi Ventures. “For many years the pharmaceutical industry has envisioned, but never achieved, a transdermal patch to replace subcutaneous administration of high-value biologics,” said Lampros Kourtis, Ph.D., a Partner at Velocity. “With its solid-state porous microneedles, Anodyne looks poised to succeed where others have failed.” This new class of microneedles was invented at Tufts University and is now the core technology of the Hero Patch™ platform at Anodyne, founded by Hojat Rezaei Nejad, Konstantinos Tzortzakis, and Jake Lombardo. By incorporating solvent-free bulk drug substance directly into microscopic porosities, Anodyne can load unprecedented amounts of the drug onto each microneedle. When the microneedle penetrates into the skin, the drug dissolves in the patient’s interstitial fluid and is systemically absorbed. “With the ability to load up to 5 mg of drug per square centimeter, we can administer pharmacologically relevant doses of high-value biologic drugs like peptides and monoclonal antibodies,” said Anodyne CEO Jake Lombardo. “Our in vivo studies also show that we can achieve desired pharmacodynamic effects.” Not only does Anodyne’s technique allow for unprecedented drug loading, but also using the solid-state form of the drug substance can lead to improved stability. This promise would circumvent the need for cold-chain distribution, a critically important challenge for developing countries, with cost-saving advantages for the global biopharmaceutical industry. Mr. Lombardo added that he and others have found the Hero Patch—in placebo form—to be painless and non-irritating. Anodyne has started collaborations with pharmaceutical companies to test particular biologics on the Hero Patch platform. The company plans to conduct clinical trials to characterize the bioequivalence, safety, and tolerability of several Hero Patch products. “Modern R&D is yielding dozens of miraculous biologic drugs, but our means of administering them has scarcely improved since the 19th century,” said Michael Singer, MD, Ph.D., a director at Anodyne. “Patients don’t like getting shots. Our healthcare system would save time and money if we didn’t have to give so many shots.” “We believe we have something to offer to all who work with biologics: patients, providers, pharmacies, and pharmaceutical companies,” said Mr. Lombardo. “We would be particularly gratified if Hero Patch could be used for needle-free delivery of biologics to children.” About Anodyne Nanotech: Anodyne is a Boston-based, preclinical-stage biotech company developing differentiated, transdermal forms of high-value drugs. The company’s patent-pending porous microneedle technology provides the first practical and cost-effective platform, Hero Patch™, to deliver clinically meaningful doses of macromolecules and small molecules. For further information: www.TheHeroPatch.com Contact Details Anodyne Nanotech Jake Lombardo +1 732-503-3865 jake.lombardo@theheropatch.com Company Website https://www.theheropatch.com

April 08, 2021 05:02 AM Eastern Daylight Time

R2 Technologies Disrupts the Aesthetics Industry with Its Groundbreaking Glacial Rx™ Treatment

R2 Technologies

R2 Technologies Inc. ("R2") the leader in CryoAesthetic™ medical devices, launches Glacial Rx™, the first revolutionary in-office CryoAesthetic™ age spot removal treatment, FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation. Developed by the pioneers of CoolSculpting and Fraxel, Glacial Rx is the first and only technology that uses Cryomodulation™ to improve skin appearance and freeze melanin at the source. The treatment harnesses the power of cold, using patented cooling technology, to suppress melanin production and remove unwanted dark spots. It also brightens, soothes, and renews skin for peak results and no downtime. “I am excited to partner with Glacial Rx to be among the first to offer this novel treatment in my practice,” says Board Certified Dermatologist Dr. Gregory Nikolaidis. “I believe it will be a game-changer in the category of cryoaesthetics, offering the opportunity to treat new patients who are looking for a comfortable solution to remove benign lesions.” The Glacial Rx System is an FDA Class II Device administered by trained healthcare professionals. Effective on most skin types, Glacial Rx delivers the best possible outcomes to remove age spots without the contraindications, risks, side effects or limitations associated with heat modalities. In partnership with one of the world’s fastest growing cosmeceutical skincare brands, Allies of Skin, Glacial Rx offers a curated topical regimen made with optimal active ingredient concentrations that can be provided alongside the treatment at the healthcare professional's discretion. The treatment consists of: Cool: The cold plate is applied to a spot for 15-20 seconds; no topical anesthetics or numbing agents needed. Calm: The cooling handpiece is gently moved across the face to reduce redness and puffiness, clearing the way for skin to better absorb potent topicals. Protect: Serums containing protective antioxidants and brightening agents can be applied, shielding the skin from environmental aggressors. Post-treatment take-home topical offerings, formulated with skin-beneficial plant derived actives, aid in skin recovery, accelerate skin’s desquamation process and re-epithelialization, and dramatically boost antioxidant activity to fight free radical damage. “It took us a long time to ensure that we were creating a best-in-class treatment, giving unparalleled results and superior experiences to our patients, and we are thrilled to finally bring this matchless innovation to market,” says Tim Holt, R2 Chief Executive Officer. According to a recent clinical study, 93% of spots improved at 2 months [1]; and another showed that 90% of patients said their skin was rejuvenated, brighter or more even at 1 month [2]. Launching this month in dermatology offices and med spas nationwide, Glacial Rx was named among ‘2021 Launches Doctors are Buzzing About’ by RealSelf, the leading and most trusted source to educate on cosmetic procedures. R2 is continuing to facilitate Glacial Rx system orders for practices to offer the treatment. Learn more about R2 Technologies and Glacial Rx at glacialskin.com and follow the company on LinkedIn. About R2 Technologies: Headquartered in Silicon Valley, R2 Technologies is a world leader in CryoAesthetic™ medical devices. In 2014, Pansend Life Sciences, LLC and Blossom Innovations, LLC founded R2 Technologies and licensed exclusive intellectual property from Massachusetts General Hospital. In 2019, R2 brought on another strategic partner, Huadong Medicine Co., Ltd. In close collaboration with these partners and the brand’s scientiﬁc founders and world-famous luminaries in aesthetic medicine, Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers. Since inception, R2 has raised $62 million in ﬁnancing led by a world-class team of experts within the aesthetics industry and was named winner of the 2nd Annual Aesthetics Tech Summit LaunchPad SBDC, hosted by Octane, a company committed to making resources, capital and mentorship available to tech and medtech startups. _________________________________________________________________________________________________ [1] Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions - Interim Analysis - Nov 2020 - TD-0993 [2] Evaluation of a New Dermal Cryotherapy System for the Treatment of Benign Pigmented Lesions - Interim report - May 2018 - TD-0992 Contact Details Linsey Tilbor Rubin +1 732-991-5294 ltilbor@rellmc.com Company Website https://glacialskin.com/

April 07, 2021 08:17 AM Eastern Daylight Time

Image

How Medicaid Compliant Annuities Work by: Jennifer Lang Financial Services

Jennifer Lang Financial Services, LLC

Contact Details Jennifer Lang Financial Services, LLC. Jennifer Lang +1 877-487-8926 mail@jenniferlangfinancialservices.com Company Website https://www.jenniferlangfinancialservices.com

April 06, 2021 10:05 AM Eastern Daylight Time

Video

Start of Lyme Disease Season Provides Heightened Risks for Americans Wanting to Go Outdoors After a Year of COVID-19 Restrictions

Quidel Corporation

As America slowly and hopefully extricates itself from the coronavirus pandemic, another health concern lies just around the corner: the start of Lyme disease season. To complicate matters, Lyme disease is one of the distinct underlying conditions that make those afflicted more vulnerable for coronavirus complications. “The warm weather of spring and summer makes everyone want to get outdoors and never more so than this year when so many of us have spent the past 12 months hunkered down in our own homes,” says Judi Tilghman, Ph.D., vice president of technology assessment at Quidel Corporation, the nation’s leading developer of rapid Lyme disease testing. “The key is to be smart in taking steps to avoid getting a tick bite in the first place and then getting tested immediately if you think you may have contracted Lyme.” Lyme disease afflicts as many as 400,000 Americans every year and can lead to a number of serious, life-threatening problems if not caught early. The challenge is that unlike a mosquito bite where people know immediately if they have been bitten, deer ticks that may carry Lyme disease are tiny—the size of a poppy seed—and symptoms may not appear for two to six weeks. That makes it critically important that anyone who spends time outdoors in heavily wooded areas—hikers, hunters, campers—or travels to such places be particularly vigilant. Some of the basic symptoms of a Lyme infection—fever, malaise, fatigue, muscle aches and headaches—can resemble COVID-19, which, according to Dr. Tilghman, is “still another reason to get tested if you feel any of these symptoms coming on. The vast majority of patients tested are negative, so getting results quickly with Quidel’s Sofia® 2 Lyme FIA test can provide peace of mind for individuals while also allowing physicians to more rapidly pursue testing and treatment for other diseases that may be causing the patient’s symptoms.” While Dr. Tilghman acknowledges that a walk in the woods, a return to playing outdoor sports on grassy fields, or camping by a river or lake is an appealing way to relieve stress from the coronavirus lockdown, she warns that such activities do come with the risk of ticks that carry Lyme and other illnesses. For anyone who intends to spend time in wooded/grassy areas during the height of Lyme disease season, she recommends: Shower right away as ticks often remain on skin for hours before attaching themselves. Showering and using a washcloth can remove unattached ticks. Check your entire body for ticks, including low-visibility areas such as the groin, underarms and the back of your neck. If you find a tick on your body, use a pair of tweezers to pull it off very gently but firmly. Watch for early signs which may include a rash (often shaped like a bullseye), flu-like symptoms, fever, body aches, headache and fatigue. Watch for later symptoms, which could appear weeks or months after being bitten. These may include a rash on areas of your body, joint pain, neurological problems, heart problems (such as an irregular heartbeat), eye inflammation, liver inflammation (hepatitis) and severe fatigue. Get to a doctor or clinic right away, and ask to be tested if you sense you might have Lyme disease. The innovative Sofia 2 Lyme FIA test is an in-office test that provides indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood. The best solution, of course, is to not get a tick bite in the first place; and there are many precautions people can take to lessen the chance of getting bitten. Dr. Tilghman says these include: wearing long pants and shirts, a hat and gloves when in wooded areas; sticking to trails and avoid walking through low bushes and long grass; putting lavender oil or insect repellants on your legs and arms and any bare skin; and tick proofing your yard by clearing brush and leaves and mowing your lawn regularly. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first rapid diagnostic point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

April 05, 2021 08:00 AM Eastern Daylight Time

Hong Kong Baptist University-led research reveals hyocholic acids arepromising agents for diabetes prediction and treatment

Media Outreach

HONG KONG SAR - Media OutReach – 1 April 2021 - A series of studies led by researchers from Hong Kong Baptist University (HKBU) have revealed that hyocholic acid and its derivatives (collectively known as HCAs), a component of bile acids that facilitate fat digestion, are a promising risk indicator of type 2 diabetes. The strong efficacy of HCAs in regulating blood glucose levels and protecting against diabetes has also been uncovered. The findings open a window for the development of HCA-based predictive markers as well as anti-diabetic drugs. The research results have been published in the international scientific journals Cell Metabolism and Nature Communications. High concentration of HCAs protects pigs from diabetes Inspired by the traditional Chinese medical book Compendium of Materia Medica, which recorded the use of pig bile to treat excessive thirst, a condition known today as diabetes, Professor Jia Wei, Chair Professor of the School of Chinese Medicine at HKBU, led research teams to conduct a series of studies on the role of HCAs in glucose homeostasis and diabetes prevention. Diabetes is characterised by high blood glucose levels. Through a series of tests conducted on 55 humans, 32 mice and 12 pigs, Professor Jia’s team confirmed that fasting blood glucose levels in pigs are significantly lower than that of humans and mice. As HCAs constitute nearly 80% of bile acids in pigs, while the proportions in humans and mice are only about 2% and 3% respectively, a negative correlation between HCAs and blood glucose levels was observed. The result indicates the potential role of HCAs in the maintenance of stable glucose levels. This may explain why pigs, unlike humans, seldom suffer from diabetes despite their low physical activity levels and consumption of a calorie-rich diet. HCAs correlate with diabetes and metabolic health To analyse the correlation between the levels of HCAs and the occurrence of diabetes in humans, data was collected from two large-scale cohort studies, namely the Shanghai Obesity Study and the Shanghai Diabetes Study. The researchers examined the serum bile acid profiles of 1,107 participants of the Shanghai Obesity Study, which was published in 2013. The participants were divided into three groups: healthy lean, healthy obese and obese with type 2 diabetes. It was discovered that the levels of serum HCAs were significantly lower in the healthy obese and obese with type 2 diabetes groups. In another study, the serum bile acids of 132 participants of the Shanghai Diabetes Study were investigated. They were all healthy (at baseline) when they were enrolled in the study between 1998 and 2001. Ten years later, 86 of them had become metabolically unhealthy, while 46 remained healthy. Analysis showed that, compared with those who remained healthy ten years later, those who had become metabolically unhealthy had significantly lower baseline levels of serum HCAs, illustrating that levels of HCAs are a strong predictor of metabolic syndromes such as diabetes. HCAs regulate blood glucose levels in animal models Through a series of laboratory experiments, the researchers looked further into the mechanisms that underpin the key role that HCAs play in regulating blood glucose levels. In an animal model experiment, the researchers suppressed the synthesis of HCAs in the livers of a group of pigs by around 30%, and they found that their blood glucose levels increased by 30% when compared with the control group. HCAs were then given to the pigs, after which their blood glucose levels eased off. Another experiment conducted by the researchers focused on the effect of HCAs on glucagon-like peptide-1 (GLP-1). GLP-1 is a hormone produced by L-cells, a type of enteroendocrine cell that enhances insulin secretion and decreases blood glucose. In a laboratory setting, different kinds of bile acids, including HCAs, were applied to L-cells, at varying levels of concentration. Results showed that at a high concentration of 50 micromolar, HCAs were the most effective at stimulating GLP-1 secretion when compared with other types of bile acids. The findings also revealed that HCAs regulate blood glucose levels by stimulating the secretion of GLP-1 and thus insulin production. Potential for diabetes prediction and treatment “The results of our studies provide evidence of how HCAs help to regulate blood glucose levels, and they have revealed the mechanism of how it is achieved at a cellular level. HCAs demonstrate promising potential, and they could be developed into an agent for the prediction and treatment of type 2 diabetes,” said Professor Jia. “As gut microbiota can regulate the metabolism of HCAs, targeting the intestines instead of the pancreas could be a prospective novel strategy for treating diabetes. We will further investigate how to increase the secretion levels of HCAs in diabetic patients by regulating the intestinal bacteria,” he added. Researchers from the Shanghai Jiao Tong University Afﬁliated Sixth People’s Hospital, Peking University, the Afﬁliated Drum Tower Hospital of Nanjing University Medical School, China Academy of Chinese Medical Sciences, China Agricultural University, Sichuan University and the University of Hawaii were also involved in the studies. Contact Details Hong Kong Baptist University Christina Wu, Communication and Public Relation Office +852 3411 7828 christinawu@hkbu.edu.hk Company Website https://www.hkbu.edu.hk/

April 01, 2021 09:00 AM Eastern Daylight Time

Image

CMMC Center of Excellence Announces Engagement Agreement with Ordr

Interoperability Clearinghouse

The Cybersecurity Maturity Model Certification Center of Excellence (CMMC COE), hosted by the Information Technology Acquisition Advisory Council (IT-AAC), a public-private partnership serving the public and private sectors for more than 15 years, is excited to announce a partnership with Ordr, an industry leader in continuous discovery, device asset inventory visibility and security of all connected devices, including unmanaged IoT, IoMT, and OT devices. This unique partnership will extend efforts by providing complete device asset inventory discovery for compliance within the CMMC COE Marketplace to improve cybersecurity protection and resilience for the global defense industrial base network of contractors, vendors, and suppliers. “We are excited to embark on this journey with Ordr”, said John Weiler, Chairman of the Board at CMMC Center of Excellence, “The foundation of CMMC starts with visibility into devices in the network and the risks they bring. This new partnership will further help advance the goals and objectives for improving the supply chain security and resilience for the US Department of Defense (DoD)”. Ord provides a purpose-built platform for asset inventory and security. It discovers and secures all connected devices -- from traditional servers, workstations and PCs to IoT, IoMT and OT devices. Using agentless and passive methods of data collection, connected devices can be automatically discovered and classified. Devices with vulnerabilities, weak ciphers/certificates or are subject to recall are identified. Ordr’s machine learning engine also maps and baselines device communication patterns to establish “Flow Genomes”. Ordr can then alert on anomalous behavior and dynamically generate micro-segmentation policies to allow devices only appropriate access. “The Ordr team is thrilled to be joining the pioneering organizations and innovators that make up the CMMC COE,” said Greg Murphy, Chief Executive Officer at Ordr. “We are working with DIB contractors, vendors, and the supplier community to enable them to meet CMMC regulations quickly and efficiently. Being a part of the CMMC COE accelerates that effort.” The executed Engagement Agreement establishes a collaborative engagement between Ordr and the CMMC COE to partner in the furthering of their respective and complementary missions and objectives regarding the adoption, use, and expansion of CMMC based cybersecurity practices, risk management, and compliance for the DIB contractor, vendor, and supplier community of providers creating a broader CMMC ecosystem globally to improve security and resilience. Specific actions will include: The co-development of CMMC advisory services, cyber training and education programs to accelerate CMMC certification, increase cyber adoption and improve cyber protection & resilience. Co-sponsor symposiums, training programs and podcasts leveraging their combined cyber and IT expertise. Host regular working groups, with other partners, to enable collaboration and communications. Establish an independent Industry Cyber Security Advisory Council with peer organizations to advise and educate leaders across government and industry on the continued evolution and effectiveness of CMMC. The CMMC-COE ( http://cmmc-coe.org ) and Ordr partnership will focus on bringing together the many disparate cyber and national security communities of interest to reduce complexity, improve awareness, and accelerate industry effort to become more cyber resilient against the growing threats from nation states and criminal enterprises. The CMMC-COE establishes both a Market Place and Knowledge Clearinghouse that will include resources that support the overall effort, including white papers; tutorials; recorded webcasts; presentations; and more that will help reduce the cost and burden on small and medium size contractors already struggling from the impact of COVID. For more information on the CMMC COE, please visit http://cmmc-coe.org, email info@cmmc-coe.org or call 703-863-3766. For more information on Ordr, please visit https://ordr.net/solutions/cmmc/, email info@ordr.net or call 833.673.7999 #### Contact Details John Weiler Executive Director, IT-AAC Chairman, CMMC COE john.weiler@it-aac.org 703-863-3766 Monica Wallace for Ordr Monica.Wallace@ruderfinn.com 650-346-8994 About Us ---------- CMMC-COE.ORG is a unique non-profit public-private partnership, with a vision to accelerate Cybersecurity Maturity Model (CMM) adoption, and reduce time & cost for security compliance for our partners by leveraging commercial best practices, CMMC standards, and innovative solutions for a measurable success. Our mission, focused on DOD mission objectives, cost containment and expeditious CMMC compliance, is to help the DIB improve cyber posture and resilience, and simplify its acquisition. The CMMC-COE is hosted by the Information Technology Acquisition Advisory Council (IT-AAC), a public/private partnership (P3) chartered in 2007 as an honest broker to reach outside the confines of the Federal IT advisories that lack dynamic reach into the Global IT Market, and dedicated to the adoption of commercial IT management standards of practice and innovations emanating from the Global IT market. Team IT-AAC has already demonstrated the value of its decade long investment, and provides a unique value to agencies seeking to achieve accelerate the transformation of legacy processes and systems. Our Just-in-Time SMEs apply an innovative suite of Technology Business Management and Agile Acquisition Processes needed to assure the business value of commercial IT. The Interoperability Clearinghouse (ICH), is the managing partner that make up the 24 NGO/SDO organizations that make up the IT-AAC. ICH provides the contract vehicles, clearances, and critical resources proven to guide sustainable, measurable and repeatable processes needed to drive better investment decisions as the speed of mission need, while aligning existing processes, methods and workforce with IT reform mandates contained in Clinger Cohen Act, FITARA, IT MGT Act, EO13838. About Ordr ------------ Digital transformation has led to the inevitable explosive increase of connected devices. The scale and diversity of these devices, and the capacity for network connectivity introduces risks. Every single device is a potential attack vector and must be secured. Ordr delivers visibility and security of all connected devices -- from traditional servers, workstations and PCs to IoT, IoMT and OT devices. Ordr discovers what devices are in the network, profiles device behavior and risks, and then automates appropriate action. Contact Details CMMC Center of Excellence Bob Dix +1 703-975-6633 bob.dix@it-aac.org Company Website https://cmmc-coe.org

March 30, 2021 08:00 AM Eastern Daylight Time

Business Council for Peace (Bpeace) Announces Sabrina Prince Elected to Its Board of Directors

Bpeace

The Business Council for Peace (Bpeace) announced today the election of Sabrina Prince, to the Board of Directors. Prince is an Executive Vice President at FCB Health Europe, a global healthcare marketing agency. She has served as a traveling volunteer Skillanthropist and member of Bpeace's Executive Council for four years. Toni Maloney, Bpeace’s CEO, noted, “Sabrina is a shrewd strategist and empathetic leader with 20+ years in healthcare marketing, including research, public relations and advertising. At Bpeace, we know her as a trusted volunteer marketing advisor to the small businesses in our portfolio, helping them recognize their brand essence and cultivate strategies to expand customer loyalty. To the Board level, she now brings perspective as a champion of diversity and inclusion, actively advocating for employee engagement and mentorship. She will be a great asset to the Board.” Prince commented, "Over the past four years with Bpeace, I have advised hospitality, healthcare and consumer goods brands at pivotal growth stages–building on their established talents and providing tools or foundational concepts they are able to customize and apply to their needs. My first Skillanthropist project was remote consultation with an Afghan business, Pakiza Dairy, a milk-processing company. And I am still holding to my promise of trying their yogurt in person someday! I look forward to working with the Board and Toni to further the impact of Bpeace." The Business Council for Peace (Bpeace) is an award-winning nonprofit working in crisis-affected communities to grow small businesses, create significant employment for all, and expand the economic power of women. More jobs mean less violence.® FCB Health Network is one of the world’s most awarded communications networks, focused on creating game-changing marketing solutions for consumers, patients and healthcare professionals. Contact Details Business Council for Peace Joan Harper +44 7572 885584 joanharper5364@gmail.com Business Council for Peace Caroline Basso +1 607.222.5791 cbasso@bpeace.org

March 29, 2021 09:15 AM Eastern Daylight Time

Image

Hong Kong Baptist University-led research unlocks the genomic secrets of organisms that thrive in extreme deep-sea environments

Media Outreach

HONG KONG SAR - Media OutReach - 29 March 2021 - A study led by scientists at Hong Kong Baptist University (HKBU) has decoded the genomes of the deep-sea clam ( Archivesica marissinica ) and the chemoautotrophic bacteria ( Candidatus Vesicomyosocius marissinica) that live in its gill epithelium cells. Through analysis of their genomic structures and profiling of their gene expression patterns, the research team revealed that symbiosis between the two partners enables the clams to thrive in extreme deep-sea environments. The research findings have been published in the academic journal Molecular Biology and Evolution. Due to the general lack of photosynthesis-derived organic matter, the deep-sea was once considered a vast "desert" with very little biomass. Yet, clams often form large populations in the high-temperature hydrothermal vents and freezing cold seeps in the deep oceans around the globe where sunlight cannot penetrate but toxic molecules, such as hydrogen sulfide, are available below the seabed. The clams are known to have a reduced gut and digestive system, and they rely on endosymbiotic bacteria to generate energy in a process called chemosynthesis. However, when this symbiotic relationship developed, and how the clams and chemoautotrophic bacteria interact, remain largely unclear. Horizontal gene transfer between bacteria and clams discovered for the first time A research team led by Professor Qiu Jianwen, Associate Head and Professor of the Department of Biology at HKBU, collected the clam specimens at 1,360 metres below sea level from a cold seep in the South China Sea. The genomes of the clam and its symbiotic bacteria were then sequenced to shed light on the genomic signatures of their successful symbiotic relationship. The team found that the ancestor of the clam split with its shallow-water relatives 128 million years ago when dinosaurs roamed the earth. The study revealed that 28 genes have been transferred from the ancestral chemoautotrophic bacteria to the clam, the first discovery of horizontal gene transfer—a process that transmits genetic material between distantly-related organisms —from bacteria to a bivalve mollusc. The following genomic features of the clam were discovered, and combined, they have enabled it to adapt to the extreme deep-sea environment: (1) Adaptions for chemosynthesis The clam relies on its symbiotic chemoautotrophic bacteria to produce the biological materials essential for its survival. In their symbiotic relationship, the clam absorbs hydrogen sulfide from the sediment, and oxygen and carbon dioxide from seawater, and it transfers them to the bacteria living in its gill epithelium cells to produce the energy and nutrients in a process called chemosynthesis. The process is illustrated in Figure 1. The research team also discovered that the clam's genome exhibits gene family expansion in cellular processes such as respiration and diffusion that likely facilitate chemoautotrophy, including gas delivery to support energy and carbon production, the transfer of small molecules and proteins within the symbiont, and the regulation of the endosymbiont population. It helps the host to obtain sufficient nutrients from the symbiotic bacteria. (2) Shift from phytoplankton-based food Cellulase is an enzyme that facilitates the decomposition of the cellulose found in phytoplankton, a major primary food source in the marine food chain. It was discovered that the clam's cellulase genes have undergone significant contraction, which is likely an adaptation to the shift from phytoplankton-derived to bacteria-based food. (3) Adaptation to sulfur metabolic pathways The genome of the symbiont also holds the secrets of this mutually beneficial relationship. The team discovered that the clam has a reduced genome, as it is only about 40% of the size of its free-living relatives. Nevertheless, the symbiont genome encodes complete and flexible sulfur metabolic pathways, and it retains the ability to synthesise 20 common amino acids and other essential nutrients, highlighting the importance of the symbiont in generating energy and providing nutrients to support the symbiotic relationship. (4) Improvement in oxygen-binding capacity Unlike in vertebrates, haemoglobin, a metalloprotein found in the blood and tissues of many organisms, is not commonly used as an oxygen carrier in molluscs. However, the team discovered several kinds of highly expressed haemoglobin genes in the clam, suggesting an improvement in its oxygen-binding capacity, which can enhance the ability of the clam to survive in deep-sea low-oxygen habitats. Professor Qiu said: "Most of the previous studies on deep-sea symbiosis have focused only on the bacteria. This first coupled clam–symbiont genome assembly will facilitate comparative studies that aim to elucidate the diversity and evolutionary mechanisms of symbiosis, which allows many invertebrates to thrive in 'extreme' deep-sea ecosystems." The research was jointly conducted by scientists from HKBU and the HKBU Institute for Research and Continuing Education, the Hong Kong Branch of the Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou), The Hong Kong University of Science and Technology, City University of Hong Kong, the Japan Agency for Marine-Earth Science and Technology, the Sanya Institute of Deep-Sea Science and Engineering, and the Guangzhou Marine Geological Survey. Contact Details Communication and Public Relations Office Wong Suk-ling +852 3411 2119 hkbunews@hkbu.edu.hk Company Website https://www.hkbu.edu.hk/

March 29, 2021 09:00 AM Eastern Daylight Time

Image

Consumer lender Fintern appoints Chief Risk Officer

Stockwood Strategy

Prior to joining Fintern, Mark was a Partner at EY, where he specialised in Credit Analytics and led EY's Quantitative Advisory Services team of 200 quantitative analysts. Since joining EY in 2005, Mark has served virtually every major UK bank on the topic of credit modelling and the use of advanced analytics. At Fintern, Mark will leverage his market-leading experience to develop Fintern's next-generation credit technology and improve access to affordable credit. Mark holds a PhD in mathematics and has been a leading advocate for the use of alternative data in fairer credit decisioning. Gerald Chappell, Fintern CEO, said "I am excited about Mark's vision for Fintern, as well as his passion for using data and analytics to fix the failings of the credit score system and improve access to affordable credit. Given his career track record, he will bring world-class analytics, artificial intelligence and strategic expertise to build on the strengths of the existing management team." On his appointment, Mark London commented: "I am delighted to be joining Fintern at this important time. Fintern's mission to transform consumer credit markets, bypassing a broken credit scoring system that unfairly excludes millions of people from affordable loans, is more relevant now than ever with the economic disruption caused by Covid-19. Using Open Banking and other alternative data we can improve financial lives by bringing affordable and responsible loans to many more people." Mark added "I am excited about Fintern's commitment to interactive lending. As CRO, I will ensure we share our insights with customers, that we will help them to make decisions that are in their best interest, and that we will provide full transparency on all our lending decisions." Michelle He, Fintern COO and CFO, said "Mark will find an amazing home here at Fintern, and a deep commitment from the entire Fintern team to challenging the traditional lending approach and helping consumers recover as we emerge from Covid-19." About Fintern Fintern is a digital consumer lender on a mission to expand access to low-cost personal finance and transform financial well-being. Fintern's next-generation credit technology takes a holistic look at each applicant’s financial situation rather than making a decision solely based on a credit score. Fintern builds relationships with customers helping them to understand their repayment capacity and credit appetite. Fintern integrates its AI platform with Open Banking to smartly connect the dots in consumers' banking data enabling Fintern to obtain the most accurate view of borrowers' affordability and spending behaviour using up to the minute transaction information. Fintern was founded in 2020 with a team from McKinsey, EY, Bank of America Merrill Lynch, HSBC and XiaoMi. Fintern is authorised and regulated by the Financial Conduct Authority, firm reference number 929244, a member of Cifas (the UK's leading anti-fraud association) and registered with the UK Information Commissioner's Office in compliance with the Data Protection Regulations 2018. Contact Details Fintern Sam Power +44 7400 122813 press@fintern.ai Company Website https://fintern.ai/

March 29, 2021 04:00 AM Eastern Daylight Time

Image

1 ... 273 274 275 276 277 ... 299

Back